News & Updates

Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
21 Jun 2022

Supplementation with lutein/zeaxanthin instead of beta carotene is safe and does not contribute to an increase in lung cancer risk while having a potential beneficial effect on the risk of progression to late age-related macular degeneration (AMD), according to data from the Age-Related Eye Disease Study 2 (AREDS2) study.

Lutein/zeaxanthin an appropriate substitute for beta carotene in AREDS2
21 Jun 2022
Treatment outcomes for nAMD, DMO, RVO poorer in clinical practice than in trials
Treatment outcomes for nAMD, DMO, RVO poorer in clinical practice than in trials
13 Jun 2022

In clinical practice, patients with neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO) see treatment outcomes that are inferior to those reported in pivotal phase 3 studies, according to a recent study.

Treatment outcomes for nAMD, DMO, RVO poorer in clinical practice than in trials
13 Jun 2022
High-frequency mutations seen in conjunctival melanoma
High-frequency mutations seen in conjunctival melanoma
06 Jun 2022

Patients with conjunctival melanoma exhibit a high frequency of BRAF and NRAS mutations, as well as ATRX and NF1 mutations, reports a study.

High-frequency mutations seen in conjunctival melanoma
06 Jun 2022
Vision impairment linked to depression, anxiety among kids
Vision impairment linked to depression, anxiety among kids
06 Jun 2022